VYGR

Voyager Therapeutics, Inc.
CAPPED RATING

Voyager's mission is to develop and deliver life-changing therapies to people around the world living with severe neurological diseases.

Voyager Therapeutics, Inc. (VYGR) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
D
Factor Score 1.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.3
EV / EBITDA -0.3
Rev Growth YoY -70.0%
Gross Margin 0.0%
Price Return 3M -46.4%
Price Return 12M -59.3%
Catalyst Signal 0.00
Market Cap $107.7M
TTM Revenue $25.1M
Price / Sales 4.3
ROE -58.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (3.0) C+ (2.7) C (2.3) D (1.2) C+ (2.6) C (2.4)
2026-11-08 B- (3.0) C+ (2.6) C (2.2) D (1.4) C+ (2.6) C (2.4)
2026-11-01 B- (3.0) C+ (2.8) C+ (2.7) D+ (1.5) C+ (2.7) C+ (2.5)
2026-10-25 B- (3.0) C+ (2.7) C+ (2.7) D (1.4) C+ (2.6) C (2.5)
2026-10-18 B- (3.0) C+ (2.7) C+ (2.7) D+ (1.5) C+ (2.6) C+ (2.5)
Page 1 of 7